Keywords: medarex, up, 225m, diff, deal, merck, co
Medarex in up to $225M C. diff deal with Merck & Co
Article | 22 April 2009
Merck & Co and fellow USA-based firm Medarex have licensed an investigational, fully-human monoclonal antibody combination developed to target and neutralize ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
